✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹23,130 Cr.
P/E
55.49
About
Dr. Lal Pathlabs Limited is a leading provider of diagnostic and healthcare services in India. The company operates a vast network across the country, offering a wide range of tests for patient diagno… Read more
Dr. Lal Pathlabs Limited is a leading provider of diagnostic and healthcare services in India.… Read more
Low
2201
52W Range
High
3654
  • Dr. Lal Pathlabs
  • Vijaya Diagnostic
  • Metropolis Health.
  • TJI Diagnostic Chains

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share
35 %
(as of Mar 18)
Diagnostic Chains Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Distribution Channel

Operational Metrics

    Select a Metric
    • Number of Diagnostic Centres (.)
    • Realization/Patient - Diagnostic Centres (Rs/Patient)
    • Number of Daily Patients - Diagnostic Centres (Ths)
    • Number of Samples - Quarterly (Million)
    Peer Comparison
    FAQs on Dr. Lal Pathlabs Ltd. Business

    Dr. Lal Pathlabs Limited is a leading provider of diagnostic and related healthcare tests and services in India, offering a comprehensive range of services to individual patients, hospitals, healthcare providers, and corporate customers.

    Dr. Lal Pathlabs major competitors are Vijaya Diagnostic, Metropolis Health., Thyrocare Tech., Krsnaa Diagnostics, Vimta Labs, Nidan Labs. & Health, Medplus Health Servi.
    Market Cap of Dr. Lal Pathlabs is ₹23,130 Crs.
    While the median market cap of its peers are ₹4,074 Crs.

    Dr. Lal Pathlabs seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Mar Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material